Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18283305 | 1.00 | HCAR2 (0.34) | HCAR2ALDH1A1KDM4EMAPTTGFBR1 | |
| SCHEMBL16160201 | 0.83 | ALDH1A1 (0.36) | HCAR2ALDH1A1KDM4EMAPTTGFBR1 | |
| SCHEMBL27714989 | 0.82 | HCAR2 (0.40) | HCAR2ALDH1A1 | |
| SCHEMBL7743142 | 0.80 | HCAR2 (0.43) | HCAR2ALDH1A1MAPTGAA | |
| Hydrochloric Acid SCHEMBL27910123 | 0.80 | HCAR2 (0.39) | HCAR2ALDH1A1 | |
| SCHEMBL23551429 | 0.77 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL9709197 | 0.77 | — | — | |
| SCHEMBL13285305 | 0.76 | ALDH1A1 (0.35) | HCAR2ALDH1A1 | |
| SCHEMBL346752 | 0.75 | KDM4E (0.33) | HCAR2ALDH1A1KDM4EGAAKDM1A | |
| SCHEMBL25271271 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | LCY BIOSCIENCES INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3303375-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BioAmber Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196962-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BIOAMBER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | COASY, ADSL, ALAD | HCAR2 219/4885ALDH1A1 157/4885KDM4E 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.